Eli Lilly and Company has emerged as in the development and tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, exhibits significant ability to improve glycemic control and reduce the risk of cardiovascular disease. The intricate produc